BR112023016353A2 - Agonistas receptores de glucocorticoides - Google Patents
Agonistas receptores de glucocorticoidesInfo
- Publication number
- BR112023016353A2 BR112023016353A2 BR112023016353A BR112023016353A BR112023016353A2 BR 112023016353 A2 BR112023016353 A2 BR 112023016353A2 BR 112023016353 A BR112023016353 A BR 112023016353A BR 112023016353 A BR112023016353 A BR 112023016353A BR 112023016353 A2 BR112023016353 A2 BR 112023016353A2
- Authority
- BR
- Brazil
- Prior art keywords
- receptor agonists
- glucocorticoid receptor
- compound
- formula
- pharmaceutically acceptable
- Prior art date
Links
- 229940124750 glucocorticoid receptor agonist Drugs 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010012438 Dermatitis atopic Diseases 0.000 abstract 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
- 208000005777 Lupus Nephritis Diseases 0.000 abstract 1
- 201000008937 atopic dermatitis Diseases 0.000 abstract 1
- 230000001363 autoimmune Effects 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
- C07J71/0026—Oxygen-containing hetero ring cyclic ketals
- C07J71/0031—Oxygen-containing hetero ring cyclic ketals at positions 16, 17
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J17/005—Glycosides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Abstract
agonistas receptores de glucocorticoides. a presente invenção refere-se a um composto de fórmula i: em que: r é hidrogênio, -p(=o)(oh)2, , ou um sal farmaceuticamente aceitável do mesmo, em que o composto de fórmula i, ou sal farmaceuticamente aceitável do mesmo, é útil para tratar doenças autoimunes e inflamatórias, tais como dermatite atópica, artrite reumatoide, lúpus eritematoso sistêmico, nefrite lúpica e doença inflamatória do intestino.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163164603P | 2021-03-23 | 2021-03-23 | |
| PCT/US2022/021285 WO2022204100A1 (en) | 2021-03-23 | 2022-03-22 | Novel glucocorticoid receptor agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023016353A2 true BR112023016353A2 (pt) | 2023-10-03 |
Family
ID=81308191
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023016353A BR112023016353A2 (pt) | 2021-03-23 | 2022-03-22 | Agonistas receptores de glucocorticoides |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220306680A1 (pt) |
| EP (1) | EP4314006A1 (pt) |
| JP (1) | JP2024510775A (pt) |
| KR (1) | KR20230148223A (pt) |
| CN (1) | CN116964067A (pt) |
| AR (1) | AR125084A1 (pt) |
| AU (1) | AU2022241660A1 (pt) |
| BR (1) | BR112023016353A2 (pt) |
| CA (1) | CA3209260A1 (pt) |
| IL (1) | IL305242A (pt) |
| TW (1) | TW202304464A (pt) |
| WO (1) | WO2022204100A1 (pt) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011513303A (ja) * | 2008-02-27 | 2011-04-28 | アストラゼネカ・アクチエボラーグ | １６アルファ，１７アルファ−アセタールグルココルチコステロイド誘導体およびその使用 |
| WO2017062271A2 (en) | 2015-10-06 | 2017-04-13 | Merck Sharp & Dohme Corp. | Antibody drug conjugate for anti-inflammatory applications |
| CA3025377A1 (en) | 2016-06-02 | 2017-12-07 | Abbvie Inc. | Glucocorticoid receptor agonist and immunoconjugates thereof |
| SG10202104259RA (en) | 2016-11-08 | 2021-06-29 | Regeneron Pharma | Steroids and protein-conjugates thereof |
-
2022
- 2022-03-15 AR ARP220100591A patent/AR125084A1/es unknown
- 2022-03-15 TW TW111109388A patent/TW202304464A/zh unknown
- 2022-03-22 BR BR112023016353A patent/BR112023016353A2/pt unknown
- 2022-03-22 US US17/700,910 patent/US20220306680A1/en active Pending
- 2022-03-22 JP JP2023558317A patent/JP2024510775A/ja active Pending
- 2022-03-22 AU AU2022241660A patent/AU2022241660A1/en active Pending
- 2022-03-22 WO PCT/US2022/021285 patent/WO2022204100A1/en active Application Filing
- 2022-03-22 CN CN202280018309.6A patent/CN116964067A/zh active Pending
- 2022-03-22 KR KR1020237032202A patent/KR20230148223A/ko active Search and Examination
- 2022-03-22 CA CA3209260A patent/CA3209260A1/en active Pending
- 2022-03-22 EP EP22716635.2A patent/EP4314006A1/en active Pending
- 2022-03-22 IL IL305242A patent/IL305242A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4314006A1 (en) | 2024-02-07 |
| AU2022241660A1 (en) | 2023-09-07 |
| TW202304464A (zh) | 2023-02-01 |
| KR20230148223A (ko) | 2023-10-24 |
| US20220306680A1 (en) | 2022-09-29 |
| CA3209260A1 (en) | 2022-09-29 |
| IL305242A (en) | 2023-10-01 |
| JP2024510775A (ja) | 2024-03-11 |
| AR125084A1 (es) | 2023-06-07 |
| CN116964067A (zh) | 2023-10-27 |
| WO2022204100A1 (en) | 2022-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2848823T3 (es) | Esteroides neuroactivos, composiciones y usos de los mismos | |
| BR112023016353A2 (pt) | Agonistas receptores de glucocorticoides | |
| MX2015011515A (es) | Diazilhidrazinas que contienen boro. | |
| BR112015024638A2 (pt) | composto, medicamento, métodos para inibir a janus cinase em um mamífero e para profilaxia ou tratamento de doença, e, uso do composto ou sal | |
| CL2021001877A1 (es) | Compuestos moduladores de fxr (nr1h4) | |
| BR112017020545A2 (pt) | composição de ácidos graxos e derivados n-acila de sarcosina para flotação aperfeiçoada de minerais não sulfetos | |
| BRPI0418152B8 (pt) | compostos de benzeno substituído por 1,2-di(cíclico), medicamento compreendendo os mesmos, agente terapêutico, inibidor de adesão celular, bem como seu uso | |
| JOP20200191A1 (ar) | مشتقات أوكسادايازولو بيريدين بها استبدال بسيكليل غير متجانسة للاستخدام كمثبطات جريلين o- أسيل ترانسفيراز (goat) | |
| BRPI0510539A (pt) | reagente de beneficiamento mineral, e, métodos para a separação seletiva de impurezas de uma mistura finamente dividida de partìculas minerais e para a separação seletiva de impurezas de argila de caulim | |
| CR20230451A (es) | Agonistas del receptor de glucocorticoides | |
| BR112022008546A2 (pt) | Composições e métodos e usos relacionados aos mesmos | |
| BR112017026985A2 (pt) | queimadores para reator de redução que permite a ocorrência separada de reação de oxidação e reação de redução e sistema de reciclagem de gás de síntese utilizando o mesmo | |
| BR112023016268A2 (pt) | Agonistas de receptores de glicocorticoides substituídos por carbóxi | |
| CO2022019194A2 (es) | Isoxazolidinas como inhibidores de ripk1 y uso de las mismas | |
| CN103781751A (zh) | 用作雌激素受体β的调节剂的二苯基取代的环己烷衍生物 | |
| BR112022012185A2 (pt) | Eletrólito aquoso para bateria de fluxo redox, uso de um eletrólito aquoso, bateria de fluxo redox e método para gerar eletricidade | |
| CL2022003055A1 (es) | Antagonistas del receptor de adenosina a2a | |
| Lamoureux et al. | Reactivity and structure of derivatives of 2‐hydroxy‐1, 4‐naphthoquinone (lawsone) | |
| BR112017003652A2 (pt) | aço para parafuso de alta resistência, e parafuso de alta resistência | |
| BR112022023276A2 (pt) | Compostos antimicrobianos esteroides catiônicos e métodos para a fabricação de tais compostos | |
| BR112018076309A8 (pt) | Compostos de geminóide e seus usos | |
| Mork et al. | Oestrogen shuts the door on SOX9 | |
| AR124717A1 (es) | Compuestos de derivados sustituidos en 4,6 de ip4 | |
| Bi et al. | Molecular docking and 3D-QSAR studies on quinolone-based HDAC inhibitors | |
| MX2012002834A (es) | Uso de compuestos esteroides para trastornos inflamatorios y autoinmunitarios. |